HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund P USD Cap

Reference Data

ISIN LU1540962054
Valor Number 35004489
Bloomberg Global ID
Fund Name HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund P USD Cap
Fund Provider HBM Partners AG Zug, Schweiz
Phone: +41 43 888 71 71
E-Mail: investorrelations@hbmpartners.com
Web: www.hbmpartners.com
Fund Provider HBM Partners AG
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s) FundPartner Solutions (Suisse) S.A.
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved.
Peculiarities

Fund Prices

Current Price * 596.01 USD 30.10.2025
Previous Price * 593.36 USD 29.10.2025
52 Week High * 596.01 USD 30.10.2025
52 Week Low * 392.02 USD 08.04.2025
NAV * 596.01 USD 30.10.2025
Issue Price * 596.01 USD 30.10.2025
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 22,582,511
Unit/Share Assets *** 18,533,994
Trading Information SIX

Performance

YTD Performance +29.07% 31.12.2024
30.10.2025
YTD Performance (in CHF) +13.97% 31.12.2024
30.10.2025
1 month +7.72% 30.09.2025
30.10.2025
3 months +27.81% 30.07.2025
30.10.2025
6 months +30.76% 30.04.2025
30.10.2025
1 year +19.87% 30.10.2024
30.10.2025
2 years +65.98% 30.10.2023
30.10.2025
3 years +52.36% 31.10.2022
30.10.2025
5 years +38.83% 30.10.2020
30.10.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE ADR 6.55%
Merus NV 6.27%
Madrigal Pharmaceuticals Inc 5.09%
Alnylam Pharmaceuticals Inc 5.06%
Xenon Pharmaceuticals Inc 4.46%
Ascendis Pharma AS ADR 4.41%
PTC Therapeutics Inc 3.41%
Genmab AS 3.36%
Scholar Rock Holding Corp 3.31%
Insmed Inc 3.20%
Last data update 30.09.2025

Cost / Risk

TER 0.0133%
TER date 31.01.2018
Performance Fee *** 15.00%
PTR
Max. Management Fee *** 1.10%
Ongoing Charges *** 2.51%
SRRI ***
SRRI date *** 30.09.2025

Breakdowns

Equity Countries ***

Equity Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)